Prospective
Students

Corporate Compliance

 
Seton Hall Law Invites you to Attend a Special Program for Members of Boards of Directors and Trustees and Their Business Advisors

RISKS TO DIRECTORS AND TRUSTEES OF HEALTH CARE & LIFE SCIENCES COMPANIES:
CORPORATE COMPLIANCE IN A DISTRESSED ECONOMY

1. In view of increasing government investigations and limited resources from a distressed economy,  is your organization’s compliance program effective? 
2. Why is a corporate compliance program an important risk management tool?
3. What are Director/Trustee responsibilities in evaluating the effectiveness of the program?
4. When does corporate conduct cross the line from civil to criminal?

PROGRAM OVERVIEW

Health care organizations doing business directly or indirectly with the federal government are urged to maintain effective corporate compliance programs as a way to minimize, if not eliminate, non-compliant behavior and to minimize corporate liability risks should non-compliant behavior occur. Delaware court decisions mention directors' role in confirming the adequacy of the company's corporate compliance program. For those health care and life sciences companies with direct or indirect relationships with federal health care programs such as Medicare and Medicaid, the federal DHHS Inspector General is imposing new contractual obligations in certain circumstances where directors are required to confirm that these compliance programs are effective. These new obligations may become the standard in other contexts. The New York State Office of the Medicaid Inspector General (OMIG) also recently published regulations requiring New York Medicaid providers to have compliance programs. In March 2009, OMIG issued the Provider Self-Disclosure Guidance.  Find out what is happening with the New Jersey Office of the Medicaid Inspector General. 

What is the benefit to companies and directors for maintaining an effective corporate compliance program? Can directors and trustees be held personally liable for misconduct even if the company has a corporate compliance program? What role should directors play in voluntary or self-disclosures to government agencies? What is involved in an effectiveness review for such programs? What are some of the recommended steps for directors to take to manage these risks? The speakers will discuss the answers to these questions.

DISTINGUISHED SPEAKERS

	Lynn Shapiro Snyder	Co-Chair: Health Care Fraud Practice Group Epstein Becker & Green P.C. - Washington, DC
	Herve Gouraige	Co-Chair: National Litigation Practice Group Epstein Becker & Green P.C. - Newark, NJ
	Kathleen M. Boozang	Professor of Law Seton Hall Law School Center for Health & Pharmaceutical Law & Policy - Newark, NJ
	Geoffrey R. Kaiser, Esq.	Managing Director, Healthcare Disputre, Compliance and Investigations, Navigant Consulting, Inc. - New York, NY
	Sandra Piersol	Director, Healthcare Dispute, Compliance and Investigations, Navigant Consulting, Inc. - Philadelphia, PA

NOTE: Seton Hall Law is an approved provider of New York Continuing Legal Education (CLE) credit. This seminar is approved for 2.0 hours of credit in Professional Practice, and is appropriate for both transitional and non-transitional attorneys. Please note that in order to receive full credit for attending this program the registrant must be present for the entire session. Appreciation is given to Epstein Becker & Green, P.C. for making available their thought leadership materials including: New DHHS OIG Integrity Obligations Imposed on Members of Health Care Board of Directors and New Jersey regulations on General Hospital Governing Body Training.